Tirzepatide (LY3298176) is a glucose-dependent in sulin nutrient polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist under development for the treatment of type 2 diabetes mellitus. Tirzepatide (LY3298176) was significantly more effective in glycemic control and weight loss than dura lutide.
Effects of TirzepatideTirzepatide is a synthetic ptide molecule containing 39 amino acids. Residues derive from GLP-1, GIP and semaglutide, and a few residues are unique . More specifically, the structure is based on the native GIP sequence and includes C20 fatty diacid moiety (eicosanedioic acid) linked via hydrolic linkers connected to lysine residue at C20 position . The peptide sequence of tirzepatide contains two non-coded amino acid residues at position 2 and 13, which are responsible for its long half-life and high affinity to albumin. The C-terminus of the peptide is amidated (Figure 2) . The molecular formula of tirzepatide is C225H348N48O68 and the molecular weight is 4813.45. Tirzepatide is the first agent that functions as a dual agonist for the two main human GLP-1 and GIP incretins, a promising drug against both T2D and obesity . It has impressive glycemic efficacy. Moreover, it is the first effective drug to have demonstrated notable body weight loss in a se 3 study in patients with T2D.
Pls me if you are interested or have any other needs.
Signup today to claim your Discount. Get Started before it's too late!
